IN8bio unveils gamma-delta T cell engager platform with lead candidate INB-619

IN8BIO, INC.

INB-600 platform expands both Vd1+ and Vd2+ T cells; lead INB-619 targets CD19 for B-cell cancers and autoimmune diseases.
Preclinical data: up to 450-fold T cell expansion, rapid and sustained B-cell depletion with target cells eradicated.
Natural lower IL-6 secretion may reduce risk of CRS and neurotoxicity vs. CAR-T and traditional TCEs.
CEO cites unmet need for deep B-cell depletion with improved safety; plans to seek partners for IND-enabling trials.
No CRS or neurotoxicities observed to date in IN8bio's ongoing gamma-delta T cell clinical programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.